Wang 2012.

Methods	Study design: parallel‐group trial Duration of follow‐up: 8 weeks Method of randomisation: not described Method of concealment of allocation: not described Blinding: not mentioned Power calculation: not mentioned Phases of the study: 1 (treatment phase)
Participants	Country of enrolment: China Setting/location: not specified Diagnostic criteria (stable angina pectoris): stable angina with coronary heart disease (macrovascular angina) Comorbidities: none Inclusion criteria: not described Exclusion criteria: not described
Interventions	Number of intervention groups: 3 Concomitant medications: conventional therapy (aspirin, cholesterol lowering agents, metoprolol) Excluded medications: not described Placebo group Intervention: placebo Duration of intervention: 8 weeks Ranolazine 500 mg group Intervention: ranolazine SR 500 mg twice daily Duration of intervention: 8 weeks Ranolazine 1000 mg group Intervention: ranolazine SR 1000 mg twice daily Duration of intervention: 8 weeks
Outcomes	Total number of outcomes: 5 (angina frequency, nitroglycerin consumption frequency, ECG total effective rate, ADR, liver/kidney function) OUTCOMES Angina episodes frequency Outcome definition: not described Method and unit of measurement: not described Time points to report: 8 weeks
Notes